Clinical Pipelines
For Patients with Spinocerebellar Degeneration
Stemchymal®
Stemchymal is a regenerative medicine product developed by Steminent Biotherapeutics (Taiwan).
In Japan, we have completed PII clinical trial in Japan, and are preparing for the approval application to deliver it to the patients as quickly as possible.
For patients with ALS/TM
iPS cell-derived neural glial cells (iGRP)
For central nerve system diseases such as ALS and TM, we are developing neural glial progenitor cells (iGRP) from iPS cells. We are under preclinical tests and, in parallel, preparing for clinical trials.
For patients with Cervical Cancer
Tumor Infiltrating Lymphocyte (TIL)
TIL therapy is a type of adoptive immunotherapy in which tumor-infiltrating lymphocytes (TILs) from the patient’s own cancer tissue are collected, cultured in large quantities ex vivo, and then reintroduced into the patient. TIL therapy has previously shown efficacy against advanced malignant melanoma. We are proceeding a clinical trial of TIL for cervical cancer.
For patients with solid tumors such as esophageal cancer
Anti-Glypican 1 Chimeric Antigen Receptor T-cell Therapy (GPC1 CAR-T)
GPC1-specific CAR-T therapy involves extracting the patient's own T cells (immune cells), genetically modifying them to recognize solid tumors, and then re-infusing them into the patient for treatment. While conventional CAR-T therapy is effective for hematologic cancers, its efficacy against solid tumors has been limited. This therapy targets GPC1 specifically expressed on various solid tumors including esophageal, lung squamous, and pancreatic cancers.